The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I received the French version of the resolutions on 17 May, via IB. The resolutions document itself is dated 13 May.
The people making the decision what (not) to RNS must be really fun at parties.
ChrisToffer, their original news release provides a bit more colour: https://live.euronext.com/en/product/equities/FR0011005933-ALXP#CompanyPressRelease-8435867
And this, from THERADIAG's 13JAN22 press release, sheds some light on how Biosynex got a foot in the door with them:
"Following acquisition of shares on the market and its participation in THERADIAG's rights issue in November 20211, BIOSYNEX held 2,468,932 shares on November 29, 2021, representing 18.82% of THERADIAG's capital2.
Within this context, constructive discussions have taken place between the management of BIOSYNEX and THERADIAG with the aim of identifying areas of cooperation and performance improvement and implementing specific action plans.
In this respect, an initial two-year distribution agreement was signed between THERADIAG and BIOSYNEX for the AMPLIQUICK SARS-CoV-2 PCR test from BIOSYNEX, which will be promoted in hospitals by THERADIAG, which benefits from a strong presence in hospitals, and in particular in the vast majority of University Hospitals.
As an extension of this first contract, BIOSYNEX and THERADIAG intend to explore the possibilities of developing joint projects.
In addition, it is already envisaged that the Board of Directors of THERADIAG will include a representative of BIOSYNEX whose appointment will be submitted to the vote of the shareholders at the latest at the next THERADIAG General Meeting."
Cash I don't know, but almost 400M Euros of revenues last year. They do know how to sell a test.
Thanks Wilson, that’s odd. He didn’t strike me as someone who would pull out here without leaving a note. Thinking positively, maybe he has gotten his hands on a new book filled with one liner words of wisdom, and has completely forgotten about the world around him. We’ll know when he reappears, hopefully.
Talking about board members missing in action: where did Troublesome go? Did I just miss his farewell message or is he out on one of his walks and soon to be back?
That was the time, not price obviously
Forgot the link: https://live.euronext.com/en/product/equities/FR0010397232-ALXP
Traders or not, somebody bought 160k shares at 10.20 in Paris. Probably not with an eye to sell them at a lower price.
Good to see, yes, but also rather obvious that we are no longer one of the few there.
As with the FDA EUAs, I am taken aback (and disappointed) that we haven’t managed (yet) to get more of our testing products on such lists. I still keep track of the FDA EUA database and see our bigger competitors raking in new approvals for a wide variety of tests almost on a monthly basis, but not us (after the one we received in March 2020 for genesig that is).
Any informed opinions here about why that may be? Is it just a matter of the approval queues taking forever? Is the company too busy with other important matters? Could it be that our later products are allowed to piggyback on the approvals we received for genesig and that, hence, we are not in a hurry to apply for additional approvals? Are we trying hard to get additional approvals but fail to receive them?
One would think that with the experience we gained through the genesig FDA/WHO approvals and the – supposedly – high quality of our products and, the latter should not be the case. But what else then can possibly explain the dearth of approvals (not counting CEs) after genesig?
Hi johnpwh, I'm not aware of any such indications. My guess would be similar as KC's.
Meanwhile, always good to see us recognized as a key player in reports like these: https://www.prnewswire.co.uk/news-releases/modified-wood-market-is-projected-to-register-a-cagr-of-9-5-and-reach-a-valuation-of-us-1-95-bn-by-2031-persistence-market-research-831925649.html
continue to accumulate, with De Eng B.V. just having breached the 10% threshold (RNS 24/1 on company website). IIs now hold some 70% of shares (https://www.accsysplc.com/investors/share-capital/).
A nice, upbeat article in a Dutch magazine too: https://www.vnci.nl/chemie-magazine/actueel/artikel?newsitemid=6220021761&title=accsys-technologies-verduurzaamt-hout-het-loopt-als-een-tierelier
There should be some good years coming here, if all pans out well.
Biosynex is out first: revenues of 383M euros for 2021, half from France, half from RoW. Expects a strong Q12022.
Trades at ~250M euros market cap, only a bit more than us.
Full press release (in French) here, scroll down to 6pm last night. https://live.euronext.com/en/products/equities/company-news?keys=&term_node_tid_depth_4%5b0%5d=21&term_node_tid_depth_4%5b1%5d=22&term_node_tid_depth_4%5b2%5d=25&combo_date_filter%5bcombo_options_range%5d=all&combo_date_filter%5bmin%5d%5bdate%5d=&combo_date_filter%5bmax%5d%5bdate%5d=
There’s a bunch of employee comments about working conditions at Novacyt and Primerdesign at glassdoor.com. Mostly quite in line with what you would expect for a company in this stage of development, but interesting nevertheless. If you don’t want to sign up with them to get access, go to google’s cached versions of the Novacyt and Primerdesign entries on the site, and then select the ‘text-only version’ and scroll down.
https://www.investorschronicle.co.uk/ideas/2021/12/09/accsys-finally-ready-to-blossom/
Thanks for sharing that Larry, quite impressive figures. Do you know why their valuation is so low? Looks ridiculous at first glance.
More likely triggered by something announced in France (Jagman2011's message of last night?): French test makers Eurobio and Biosynex are also down, and quite a bit more than Novacyt actually.
Ventura1: am I right to take that as a rhetorical question:)